EHAB

BEARISH

$13.74 Live

Enhabit, Inc. · NYSE

Target $13.8 (+0.4%)

$6.47 52W Range $14.22

EHAB Enhabit, Inc. - Fundamental Analysis

BEARISH

Console Chart News

EHAB Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Medical Care Facilities

Current Price Live

$13.74

Analyst Target

$13.8

+0.4% Upside

52W High

$14.22

52W Low

$6.47

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026

Market cap

$703.84M

P/E

N/A

ROE

-0.5%

Profit margin

-0.4%

Debt/Equity

0.89

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

EHAB exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the stock has seen a significant 1-year price surge (+78.4%), this momentum is disconnected from core profitability, as evidenced by a negative profit margin (-0.43%) and negative ROE (-0.46%). The lack of a Graham Number and the absence of an Altman Z-Score, combined with bearish insider selling, suggest a speculative valuation. The recent price action likely reflects merger speculation mentioned in SEC filings rather than organic growth.

Key Strengths

Strong 1-year price momentum (+78.4%)

Low Price-to-Sales ratio (0.66)

Healthy liquidity ratios (Current Ratio 1.63, Quick Ratio 1.49)

Positive operating margin (5.33%) despite negative net profit

Recent history of beating earnings estimates in 2 of the last 4 quarters

Key Risks

Critical financial health failure (Piotroski F-Score 2/9)

Negative net profit margins and negative Return on Equity

Stagnant revenue growth (4.70% YoY)

Bearish insider sentiment with net selling activity

High forward P/E (22.12) relative to current negative profitability

AI Fair Value Estimate

Based on comprehensive analysis

$13.8

+0.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative/Weak

Key drivers: Piotroski F-Score, Negative ROE, Insider Selling, Merger Speculation

Confidence

90%

Value

45/100

Trades at a low multiple of sales but lacks earnings support.

Positives

Low P/S ratio of 0.66

Watchpoints

No Graham Number available
Forward P/E is high for the growth profile

Future

40/100

Growth is inconsistent and revenue expansion is sluggish.

Positives

YoY EPS growth recovery (+250%)

Watchpoints

Slow revenue growth (4.7%)
Recent Q/Q EPS decline (-17.6%)

Past

30/100

Long-term value destruction despite recent short-term rally.

Positives

Strong 6-month and 1-year price recovery

Watchpoints

5-year price change is -45%

Health

15/100

Deterministic health scores indicate high operational risk.

Positives

Current ratio above 1.5

Watchpoints

Piotroski F-Score of 2/9 is critically low
Negative ROE

Dividend

0/100

Non-dividend paying stock.

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$13.74

Analyst Target

$13.8

Upside/Downside

+0.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for EHAB and closest competitors.

Updated 2026-04-24

Company	5Y	3Y	1Y	6M	1M	1W
EHAB Enhabit, Inc. Primary	-45.0%	+11.0%	+78.4%	+60.5%	+0.5%	+0.1%
PSNL Personalis, Inc. Peer	-68.6%	+152.1%	+111.0%	-26.3%	-3.3%	+11.8%
BBNX Beta Bionics, Inc. Peer	-32.5%	-32.5%	-32.5%	+7.5%	-48.7%	-13.7%
GYRE Gyre Therapeutics, Inc. Peer	-40.0%	+134.6%	+1.4%	-7.2%	-11.3%	+3.8%
PRME Prime Medicine, Inc. Peer	-75.2%	-72.0%	+207.3%	-30.1%	+7.9%	+11.1%

EHA

Enhabit, Inc.

Primary

-45.0%

+11.0%

+78.4%

+60.5%

+0.5%

+0.1%

PSN

Personalis, Inc.

Peer

-68.6%

+152.1%

+111.0%

-26.3%

-3.3%

+11.8%

BBN

Beta Bionics, Inc.

Peer

-32.5%

+7.5%

-48.7%

-13.7%

GYR

Gyre Therapeutics, Inc.

Peer

-40.0%

+134.6%

+1.4%

-7.2%

-11.3%

+3.8%

PRM

Prime Medicine, Inc.

Peer

-75.2%

-72.0%

+207.3%

-30.1%

+7.9%

+11.1%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

22.12

N/A

1.31

0.66

1.12

13.71

$703.84M

Profitability

Profit margins and return metrics

Profit Margin -0.43%

Operating Margin 5.33%

Gross Margin 49.04%

ROE -0.46%

ROA 3.33%

Growth

Revenue and earnings growth rates

Revenue Growth +4.7%

Earnings Growth N/A

Q/Q Revenue Growth +4.73%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.89

Moderate

Current Ratio

1.63

Good

Quick Ratio

1.49

Good

Cash/Share

$0.86

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.3B

Gross Margin

48.7%

Op. Margin

5.3%

Net Margin

-14.3%

Total Assets

$1.2B

Liabilities

$0.6B

Equity

$0.5B

Debt/Equity

1.13x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

75%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06

$N/A

2026-03-04

$0.14

-1.3% surprise

2025-11-05

$0.17

+42.4% surprise

2025-08-06

$0.13

+30.8% surprise

Healthcare Sector Comparison

Comparing EHAB against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)

Return on Equity (ROE)

-0.46%

This Stock

-89.9%

Sector Avg

-99.5% (Below Avg)

Profit Margin

-0.43%

This Stock

-16.4%

Sector Avg

-97.4% (Weaker)

Debt to Equity

0.89

This Stock

2.71

Sector Avg

-67.3% (Less Debt)

Revenue Growth

4.7%

This Stock

126.74%

Sector Avg

-96.3% (Slower)

Current Ratio

1.63

This Stock

4.53

Sector Avg

-64.1% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
EHAB Enhabit, Inc.	BEARISH	$703.84M	-	-0.5%	-0.4%	$13.74
PSNL Personalis, Inc.	BEARISH	$704.48M	-	-35.0%	-116.7%	$6.73	Compare
BBNX Beta Bionics, Inc.	BEARISH	$702.63M	-	-47.5%	-87.9%	$15.96	Compare
GYRE Gyre Therapeutics, Inc.	BEARISH	$711.9M	369.5	8.2%	4.3%	$7.39	Compare
PRME Prime Medicine, Inc.	BEARISH	$687.9M	-	-146.8%	-%	$3.81	Compare

EHAB Enhabit, Inc.

BEARISH

Mkt Cap

$704M

P/E

ROE

-0.5%

Price

$13.74

PSNL Personalis, Inc.

Compare with EHAB

BBNX Beta Bionics, Inc.

Compare with EHAB

GYRE Gyre Therapeutics, Inc.

Compare with EHAB

PRME Prime Medicine, Inc.

Compare with EHAB

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-10	SCHOCHET BARRY P	Director	Stock Award	1,698	$23,755
2026-04-10	OHLENDORF MARK WILLIAM	Director	Stock Award	1,340	$18,747
2026-04-10	ELSON CHARLES M	Director	Stock Award	1,340	$18,747
2026-04-10	MCGUIGAN STUART M	Director	Stock Award	1,340	$18,747
2026-04-10	HOEFLINGER ERIN P	Director	Stock Award	1,698	$23,755
2026-04-10	BOLTON JEFFREY	Director	Stock Award	2,680	$37,493
2026-04-10	RUSH GREGORY S	Director	Stock Award	1,787	$25,000
2026-04-10	RODGERS STEPHAN S.	Director	Stock Award	1,340	$18,747
2026-03-11	MCQUIDDY COLLIN	Officer	Sale	1,403	$19,095
2026-03-10	JOLLEY JULIE DIANE	Officer	Sale	5,586	$76,137
2026-03-06	JACOBSMEYER BARBARA ANN	Chief Executive Officer	Stock Award	32,789	$446,258
2026-03-06	JOLLEY JULIE DIANE	Officer	Stock Award	10,030	$136,508
2026-03-06	JOLLEY JULIE DIANE	Officer	Stock Award	22,080	$300,509
2026-03-06	MARION TANYA RENEE	Officer	Stock Award	10,287	$140,006
2026-03-06	KALVAITIS JEANNE LOUISE	Officer	Stock Award	5,603	$76,257

SCHOCHET BARRY P

Director

Stock Award

2026-04-10

1,698 shares · $23,755

OHLENDORF MARK WILLIAM

Director

Stock Award

2026-04-10

1,340 shares · $18,747

ELSON CHARLES M

Director

Stock Award

2026-04-10

1,340 shares · $18,747

MCGUIGAN STUART M

Director

Stock Award

2026-04-10

1,340 shares · $18,747

HOEFLINGER ERIN P

Director

Stock Award

2026-04-10

1,698 shares · $23,755

BOLTON JEFFREY

Director

Stock Award

2026-04-10

2,680 shares · $37,493

RUSH GREGORY S

Director

Stock Award

2026-04-10

1,787 shares · $25,000

RODGERS STEPHAN S.

Director

Stock Award

2026-04-10

1,340 shares · $18,747

MCQUIDDY COLLIN

Officer

Sell

2026-03-11

1,403 shares · $19,095

JOLLEY JULIE DIANE

Officer

Sell

2026-03-10

5,586 shares · $76,137

JACOBSMEYER BARBARA ANN

Chief Executive Officer

Stock Award

2026-03-06

32,789 shares · $446,258

JOLLEY JULIE DIANE

Officer

Stock Award

2026-03-06

10,030 shares · $136,508

JOLLEY JULIE DIANE

Officer

Stock Award

2026-03-06

22,080 shares · $300,509

MARION TANYA RENEE

Officer

Stock Award

2026-03-06

10,287 shares · $140,006

KALVAITIS JEANNE LOUISE

Officer

Stock Award

2026-03-06

5,603 shares · $76,257

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-04-16

eHealth, Inc. (EHAB) likely filed this 8-K to report its first-quarter financial results for 2026.

10-K

2026-03-05

Enhabit, Inc. filed its annual 10-K on March 5, 2026, which includes standard disclosures regarding its financial condition, operations, and market risks. While specific financial metrics were not provided in the excerpts, the filing addresses critical risk factors, cybersecurity, and legal proceedings.

8-K

2026-03-05

EHAB filed an 8-K on March 5, 2026, likely to announce its annual financial results.

8-K

2026-03-04

eHealth, Inc. (EHAB) filed an 8-K on March 4, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2026-02-27

eHealth, Inc. (EHAB) filed an 8-K on February 27, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2026-02-23

EHAB filed a current report on Form 8-K, likely announcing its annual financial results for the previous fiscal year.

8-K

2026-02-12

EHAB filed an 8-K on February 12, 2026, likely to announce its annual or quarterly financial results.

8-K

2025-12-09

eHealth, Inc. reported its third-quarter financial results.

10-Q

2025-11-05

EHAB filed its quarterly 10-Q report on November 5, 2025, which includes disclosures regarding risk factors and the unregistered sale of equity securities. Specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K

2025-11-05

eHealth, Inc. (EHAB) filed an 8-K on November 5, 2025, likely to announce its third-quarter financial results.

8-K

2025-09-29

10-Q

2025-08-07

8-K

2025-08-06

8-K

2025-08-06

8-K

2025-06-26

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

5 analysts

TD Cowen

2026-03-06

down

Buy Hold

UBS

2026-02-24

down

Buy Neutral

Jefferies

2026-02-23

down

Buy Hold

Leerink Partners

2026-02-23

Maintains

Market Perform Market Perform

Oppenheimer

2026-01-22

Perform Outperform

TD Cowen

2026-01-13

Hold Buy

UBS

2026-01-08

Neutral Buy

Past News Coverage

Recent headlines mentioning EHAB from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

EHAB

EHAB Enhabit, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!